INmune Bio reports FY2023 net loss of $30.0M; pipeline updates for XPro, INKmune

Inmune Bio, Inc.

Net loss for FY2023 was $30.0M, up from $27.3M in FY2022; R&D spend rose to $20.3M.
Cash and equivalents at Dec 31, 2023: $35.8M; shares outstanding ~18.0M as of Mar 28, 2024.
XPro AD02 Alzheimer's trial on track for mid-2024 enrollment completion; top-line data ~6 months later.
Phase I/II INKmune mCRPC trial enrolled first patient Dec 2023; cohort 2 to open after DSMC review in mid-April.
Company winding down AML program to focus on prostate cancer and other solid tumors.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Inmune Bio, Inc. reported the year ended December 31, 2023 results: net income approximately $30.0 million.

Period: the year ended December 31, 2023
Net income: approximately $30.0 million
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders for the year ended December 31, 2023, was approximately $30.0 million, compared to approximately $27.3 million during the year ended December 31, 2022.

View on SEC.gov

268 earnings releases filed in the last 30 days. Browse all earnings releases →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-027960

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.